These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 1279309)

  • 21. Long-term antiarrhythmic pharmaco-therapy guided by Holter monitoring in patients with malignant ventricular arrhythmias and ischemic heart disease.
    Trusz-Gluza M; Gasior Z; Wnuk-Wojnar AM; Filipecki A; Szydło K; Giec L
    Mater Med Pol; 1992; 24(4):229-32. PubMed ID: 1308049
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Validity and limits of invasive pharmacological tests in the treatment of malignant ventricular hyperkinetic arrhythmias].
    Disertori M; Vergara G; Inama G; Guarnerio M; Furlanello F; Botti G; Bonatti V; Rolli A
    G Ital Cardiol; 1983; 13(4):311-4. PubMed ID: 6884675
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Combination of celiprolol and amiodarone in the treatment of recurrent ventricular tachycardia].
    Tonet J; Hidden F; Naditch L; Coutte R; Himbert C; Frank R
    Ann Cardiol Angeiol (Paris); 1996 Jan; 45(1):18-23. PubMed ID: 8815771
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The utility of serum drug level monitoring during therapy with class III antiarrhythmic agents.
    Follath F
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S41-3. PubMed ID: 1279308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amiodarone for the emergency care of children.
    Lane RD; Nguyen KT; Niemann JT; Bolte RG; Etheridge SP; Gausche-Hill M
    Pediatr Emerg Care; 2010 May; 26(5):382-9. PubMed ID: 20453797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia.
    Nademanee K; Hendrickson J; Kannan R; Singh BN
    Am Heart J; 1982 Jun; 103(6):950-9. PubMed ID: 7081035
    [No Abstract]   [Full Text] [Related]  

  • 27. Parenteral antiarrhythmic drug therapy in ventricular tachycardia/ventricular fibrillation: evolving role of class III agents--focus on amiodarone.
    Scheinman MM
    J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):914-9. PubMed ID: 8548112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long term efficacy of class I antiarrhythmic agents and amiodarone in patients with malignant ventricular arrhythmias.
    Schmidt G; Goedel-Meinen L; Jahns G; Linné R; Schaudig U; Kein G; Baedeker W; Wirtzfeld A
    Drugs; 1985 Mar; 29 Suppl 3():37-46. PubMed ID: 3996244
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy.
    Singh BN
    Am J Cardiol; 1993 Nov; 72(16):114F-124F. PubMed ID: 8237824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance and incidence of concordance of drug efficacy predictions by Holter monitoring and electrophysiological study in the ESVEM Trial. Electrophysiologic Study Versus Electrocardiographic Monitoring.
    Reiter MJ; Mann DE; Reiffel JE; Hahn E; Hartz V
    Circulation; 1995 Apr; 91(7):1988-95. PubMed ID: 7895357
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use.
    Chow MS
    Ann Pharmacother; 1996 Jun; 30(6):637-43. PubMed ID: 8792951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Disparity between the clinical and electrophysiologic effects of amiodarone in the treatment of recurrent ventricular tachyarrhythmias.
    Hamer AW; Finerman WB; Peter T; Mandel WJ
    Am Heart J; 1981 Dec; 102(6 Pt 1):992-1000. PubMed ID: 7315716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of Holter monitoring in predicting long-term efficacy and inefficacy of amiodarone used alone and in combination with class 1A antiarrhythmic agents in patients with ventricular tachycardia.
    Kim SG; Felder SD; Figura I; Johnston DR; Waspe LE; Fisher JD
    J Am Coll Cardiol; 1987 Jan; 9(1):169-74. PubMed ID: 3794093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive value of electrophysiologic testing in the treatment of drug-refractory ventricular arrhythmias with amiodarone.
    Borggrefe M; Breithardt G
    Eur Heart J; 1986 Sep; 7(9):735-42. PubMed ID: 3769956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiarrhythmic drug selection.
    Podrid PJ
    Annu Rev Med; 1987; 38():1-17. PubMed ID: 3555284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative evaluation of antiarrhythmic agents.
    Morganroth J
    Drugs; 1985; 29 Suppl 4():14-20. PubMed ID: 2861076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term continuous electrocardiographic recordings and electrophysiologic testing to select patients with ventricular arrhythmias for drug trials and to determine antiarrhythmic drug efficacy.
    Bigger JT
    Am J Cardiol; 1986 Aug; 58(5):58C-65C. PubMed ID: 3529907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New approaches to antiarrhythmic therapy.
    Zipes DP
    N Engl J Med; 1981 Feb; 304(8):475-6. PubMed ID: 7453773
    [No Abstract]   [Full Text] [Related]  

  • 39. Antiarrhythmic agents in older patients. Current state of knowledge.
    Kim CH; Daubert JP; Akiyama T
    Drugs Aging; 1994 Jun; 4(6):462-9. PubMed ID: 7521233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The CASCADE Study: randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators.
    Greene HL
    Am J Cardiol; 1993 Nov; 72(16):70F-74F. PubMed ID: 8237833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.